Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endo USA Inc., a Keenova Therapeutics Company
An Open-Label Safety and Tolerability Study of Immediate-Release and Extended-Release Oxymorphone in Opioid-Tolerant Pediatric Subjects With Chronic Pain.
Age
6–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have chronic cancer or non-cancer pain, currently requiring treatment of pain with a strong opioid for at least 5 days (3 of 5 days at a dose greater than or equal to 45 mg/daily (qd) oral morphine equivalent)
Weigh at least 50 kg
Expected to continue to require a strong opioid for pain relief for at least 4 weeks and up to 4 months.
You may not be if
Have a life expectancy \<4 weeks
Plan to undergo a surgical procedure within 3 days of study entry or during the Titration Period
Have dysphagia or difficulty swallowing whole tablets
